Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia

Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia

Background: The CXCR4/SDF-1α axis plays a vital role in the retention of stem cells within the bone marrow and downstream activation of cell survival signaling pathways. LY2510924, a second generation CXCR4, showed significant anti-leukemia activity in a murine AML model.Methods: We conducted a phas...

Full description

Bibliographic Details
Main Authors: Prajwal Boddu, Gautam Borthakur, Mythili Koneru, Xuelin Huang, Kiran Naqvi, William Wierda, Prithviraj Bose, Elias Jabbour, Zeev Estrov, Jan Burger, Yesid Alvarado, April Deshmukh, Ami Patel, Antonio Cavazos, Lina Han, Jorge E. Cortes, Hagop Kantarjian, Michael Andreeff, Marina Konopleva
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-09-01
Series:Frontiers in Oncology
Subjects:
LY2510924
idarubicin
cytarabine
relapsed refractory
acute myeloid leukemia
CXC4
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2018.00369/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2018.00369/full

Similar Items